Immunotherapy with checkpoint inhibitors prolong cancer survival, particularly in melanoma and lung tumors. They modify the immune system but may trigger immune-related adverse events (IrAEs), including death. We reviewed PubMed for IrAEs from 2005-2017. We found that dermatologic, endocrine and gastrointestinal systems most affected. For single drugs, ipilimumab, nivolumab and pembrolizumab account for the majority. In two-drug combinations, Pembrolizumab and Nivolumab, Nivolumab and Ipilimumab and Pembrolizumab and Ipilimumab account for 58% of adverse events.

Learning Objective: Learn about the immune-related adverse events associated with immunotherapy with checkpoint inhibitors, common organ systems involved and the drugs or drug combinations associated with them.


Paul Fontelo (Presenter)
Nantional Library of Medicine

Fang Liu, Nantional Library of Medicine

Presentation Materials: